Novyra Pharmachem logo

Novyra Pharmachem financials: balance sheet, profit and loss, cash flow

BSE: 519353Agricultural Food & other ProductsSmall Cap

NOVYRA PHARMACHEM LIMITED · Face value ₹10 · Listed Apr 1994
Last close ₹8.08down ₹0.42 (4.94%)

Share price at the BSE close on 28 Oct 2026. Previous close ₹8.50.

28 Oct: open ₹8.08, high ₹8.08, low ₹8.08

52-week range of traded prices to 28 Oct 2026
₹7.12Low, 28 Oct 2025₹16.55High, 23 Mar 2026
Market cap
₹5.11 Cr4,706th largest listed
P/E
Lossover the last 12 months
P/B
8.64
Dividend yield
Nonein the last 12 months
ROE
−166.3%
ROCE
−906.7%
Debt to equity
0.00
Volume, BSE
200

Novyra Pharmachem's financial statements for the 9 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them. It had no borrowings at 31 Mar 2026.

10 years at a glance

₹ crore, years to March.Novyra Pharmachem annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Mar 171.70.0Mar 181.7−0.10Mar 190.20.00Mar 20155.90Mar 210.20.00Mar 220.20.00Mar 230−0.20Mar 240−0.10.2Mar 250.1−5.40Mar 26
Peak revenue ₹15 Cr, year to Mar 2021; lowest ₹0.00 Cr, year to Mar 2024A loss in 6 of the 9 years with results on record

Operating and net margin, per cent

  • Operating margin
  • Net margin
39.8%−5,180.1%−6.0%1.3%39.8%−10.2%30.0%−5,180.1%−2.2%−7.5%−11.9%39.5%2.3%7.7%−5,147.3%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue0.1
  2. Employee costs−0.2
  3. Other expenses−5.4
  4. Operating profit−5.4
  5. Depreciation0.0
  6. Other income+0.1
  7. One-off items0.0
  8. Finance costs0.0
  9. Profit before tax−5.4
  10. Tax0.0
  11. Net profit−5.4

What the company owns

  • Plant, investments and other assets₹1 Cr
  • Cash and bank₹0 Cr
  • Receivables₹0 Cr

What pays for it: net worth and liabilities

  • Owed to suppliers₹1 Cr
  • Net worth₹1 Cr

Novyra Pharmachem business segments, year to Mar 2026

A reportable segment is a line of business the company must report on its own. Standalone, ₹ crore, as the company reports them. A segment at a loss has no share of profit.Novyra Pharmachem segment results by quarter

Revenue by segment

₹0.17 CrTotal
  • Tea Estate₹0.12 Cr73.1% of total
  • Real Estate₹0.04 Cr20.9% of total
  • Pharma₹0.01 Cr6.0% of total

Profit by segment

  • Real Estate₹0.04 Cr77.8% of total
  • Pharma₹0.01 Cr22.2% of total

Segment results by year

Standalone, ₹ crore, years to March.

  • Tea Estate

    Revenue, ₹ crore
    Profit, ₹ crore
  • Real Estate

    Revenue, ₹ crore
    Profit, ₹ crore
  • Pharma

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue of all businesses–––––––0.2
Company revenue, as in its results1.70.215.00.20.2––0.1
Revenue–––––––0.1
Profit–––––––−4.5
Margin–––––––−3,646.0%
Return on capital–––––––−602.8%
Assets–––––––0.7
Liabilities–––––––0.0
Capital employed–––––––0.7
Revenue–––––––0.0
Revenue–––––––0.0
–––––––0.0
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Standalone, ₹ crore, years to March. No results on record for the year to Mar 2017. The last column is the twelve months to Jun 2026, the latest four quarters added.Novyra Pharmachem quarterly results

₹ croreMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 2 MayJun 2026Twelve monthsFiled 14 Aug
Revenue from operations1.71.70.215.00.20.20.00.00.11.9
–1.80.19.00.20.10.10.15.57.2
Materials and goods bought1.20.80.00.00.00.00.00.00.01.7
Employee costs–0.80.02.90.00.00.00.00.20.1
Other expenses–0.20.16.10.10.10.10.05.45.4
Operating profit before depreciation–−0.10.06.00.00.0−0.1−0.1−5.4−5.3
Operating margin–−6.0%1.3%39.8%−10.2%30.0%––−5,180.1%–
Materials, % of revenue–46.2%2.5%0.0%0.0%0.0%––0.0%–
Employee costs, % of revenue–47.3%17.2%19.3%32.1%26.1%––144.3%–
Other expenses, % of revenue–12.5%79.0%40.9%78.2%43.8%––5,135.8%–
Depreciation and amortisation0.00.00.02.00.00.00.00.00.00.0
Operating profit after depreciation–−0.10.04.00.00.0−0.2−0.1−5.4−5.4
Other income–0.00.02.60.00.00.00.00.10.0
Finance costs–0.00.00.00.00.00.00.00.00.0
One-off items–0.00.00.00.00.00.00.00.00.0
Profit before tax0.0−0.10.06.60.00.0−0.2−0.1−5.4−5.4
Tax–0.00.00.70.00.00.00.00.00.0
Net profit0.0−0.10.05.90.00.0−0.2−0.1−5.4−5.4
Net margin−2.2%−7.5%−11.9%39.5%2.3%7.7%––−5,147.3%–
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2018: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 2 May
666,05,18666661
Share capital666,19,75566666
Reserves00−14,5690000−6
Borrowings00000000
0014,13200001
00000000
Total assets666,19,31866661
666,02,24066661
0017,07800001
Net debt00−10,69300000
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 2 May
6.63−0.600.02−0.14−0.19−3.72
6.63−0.600.01−0.14−0.14−3.72
–––0.00−0.111.62
Receivables–––0.000.080.05
Payables–––0.07−0.070.87
Other working capital–––−0.07−0.110.71
Interest paid–0.000.000.00−0.050.00
Capital spending–0.000.000.000.000.00
Free cash flow6.63−0.600.02−0.14−0.19−3.72
–0.290.150.000.083.79
–0.00−0.020.000.15−0.15
Dividends paid–0.000.000.000.000.00
Shares bought back–0.000.000.000.000.00
Shares issued–0.000.000.000.000.00
Net change in cash6.63−0.300.14−0.140.05−0.09
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 2 May
Earnings per share₹0.00–₹0.01₹0.00₹0.02−₹0.03−₹0.10−₹8.49
Diluted earnings per share––₹0.01₹0.00₹0.02−₹0.03−₹0.10−₹8.49
Book value per share₹9.50₹9.47₹9,56,059.51₹9.60₹9.62₹9.36₹9.46₹0.94
Shareholder yield–––0.0%0.0%0.0%–0.0%
Market cap at the year end (₹ crore)–––2.966.142.11–9.48
Earnings per share is left blank for the year to Mar 2020: the earnings per share is stated as 0 while the period's profit or loss comes to at least half a paisa a share, so the 0 stands in for a figure the filing does not give.

Ratios

Standalone, years to March.Novyra Pharmachem PE ratio and valuation

RatioMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 2 May
Revenue growth−0.5%−91.3%9,900.0%−99.0%0.0%−100.0%––
Operating profit growth––3,01,748.5%–––––
Net profit growth–––−99.9%242.9%–––
Earnings per share growth–––−90.0%1,900.0%–––
−2.1%−0.3%0.0%0.0%0.2%––−166.5%
–1.8 pts0.3 pts0.0 pts0.2 pts–––
From the net margin–−1.3 pts1.3 pts0.0 pts0.0 pts–––
From asset turnover–3.1 pts−1.0 pts0.0 pts0.2 pts–––
From borrowing–0.0 pts0.0 pts0.0 pts0.0 pts–––
Return on capital employed−2.1%−0.3%0.0%−0.6%0.4%−2.7%−1.9%−918.2%
Cash conversion––111.8%−17,638.8%148.0%–––
Debt to equity0.000.000.000.000.000.000.030.00
Receivable days311621,55,368192346––38
Inventory days20––––––
Payable days610––––––
Cash conversion cycle, days−28162––––––
Working capital days−7−8−1,88,507142226––−1,035
Asset turnover0.280.020.000.000.020.000.000.03
Assets per rupee of net worth1.031.021.021.021.021.031.031.16
Sales per rupee of plant0.340.030.000.030.030.000.000.14
Capital spending to depreciation–––0.000.000.000.000.00
Plant being built, % of plant in use0.0%–0.0%0.0%0.0%0.0%0.0%–
No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−143.4%
Measure5 years3 years
Revenue growth, yearly rate−63.0%−11.4%
Return on capital employed, average−184.6%−307.6%
Asset turnover, average0.010.01
Debt to equity, average0.010.01

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−4.62−4.04−3.72
Cash from investing4.313.873.79
Cash from financing−0.020.00−0.15
Capital spending0.000.000.00
Dividends paid0.000.000.00
Shares bought back0.000.000.00
Shares issued for cash0.000.000.00
Borrowings repaid0.000.000.00

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–637–––
Altman Z-scorePublished threshold 1.81––12.68–6.49–−11.12
Beneish M-scorePublished threshold −1.78–1,079.30−3.84−1.87–––
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––0.00−2.48−0.370.67−145.06
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––1.02–––
Receivables growth less revenue growthOur threshold 0 percentage points36.8895,64,149.05−1.0080.2298.24––
Inventory growth less cost-of-goods growthOur threshold 0 percentage points−0.46––––––
Other current assets growth less revenue growthOur threshold 5 per cent of revenue0.000.0013.15−8.95––111.30
Assets under construction, years of additionsOur threshold 2 years of additions–0.00––0.00––
Effective tax ratePublished threshold 17.16 per cent–10.5615.7164.55–––
Tax charged less tax paid, % of profitOur threshold 10 percentage points––15.7164.55–––
A threshold marked as ours has no published figure; it is the line we read the check against.